微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 56.1% | -11.12% | -3.22% | 61/158 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 57.97% | -9.09% | -1.74% | 54/158 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 58.99% | -6.36% | -0.99% | 54/158 | 22.73% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 59.58% | -8.14% | -5.61% | 55/158 | 33.18% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 63.12% | -1.97% | -1% | 43/158 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 63.76% | -2.61% | 1.21% | 44/158 | 51.38% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 63% | -1.57% | -2.88% | 45/158 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 64.87% | 0.79% | 0.74% | 43/158 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 64.39% | -4.36% | -1.65% | 43/158 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 65.47% | -9.04% | 2.29% | 47/158 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 64% | -14.41% | -0.55% | 50/158 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 64.36% | -14.85% | -4.41% | 49/158 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 67.32% | -15.19% | -6.46% | 41/158 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 71.97% | -9.13% | -3.75% | 39/158 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 74.78% | 2% | -1.06% | 28/158 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 75.58% | -2.66% | -4.79% | 30/158 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 79.38% | 2% | 0.22% | 17/158 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 79.21% | -1.14% | 2.01% | 24/158 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 77.65% | 2% | -3.09% | 20/158 | 54.11% | 泽璟制药 | 99.96% | 行业排名> |
| 2019-12-31 | 80.12% | 13.87% | 13.87% | 17/158 | -1222.98% | 微芯生物 | 95.14% | 行业排名> |
| 2018-12-31 | 70.36% | 6.34% | 6.34% | 34/158 | -208.09% | 多瑞医药 | 95.59% | 行业排名> |
| 2017-12-31 | 66.17% | 2% | 2% | 30/158 | 52.32% | 微芯生物 | 95.81% | 行业排名> |